MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI), today announced that results of the Phase II clinical trial evaluating Ostarine™ (MK-2866) for the treatment of cancer cachexia will be presented at ENDO 2009, The Endocrine Society’s Annual Meeting, being held in Washington, DC June 10-13 at the Walter E. Washington Convention Center.
